Candriam Luxembourg S.C.A. reduced its stake in shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 48.1% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 148,000 shares of the biopharmaceutical company’s stock after selling 137,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Achillion Pharmaceuticals were worth $1,154,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of the stock. Creative Planning boosted its position in shares of Achillion Pharmaceuticals by 0.8% in the second quarter. Creative Planning now owns 133,175 shares of the biopharmaceutical company’s stock valued at $1,039,000 after buying an additional 1,000 shares during the period. Legal & General Group Plc raised its stake in shares of Achillion Pharmaceuticals by 15.7% in the first quarter. Legal & General Group Plc now owns 18,010 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 2,443 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Achillion Pharmaceuticals during the first quarter worth $101,000. Fox Run Management L.L.C. acquired a new stake in shares of Achillion Pharmaceuticals during the second quarter worth $105,000. Finally, Royal Bank of Canada raised its stake in shares of Achillion Pharmaceuticals by 29.3% in the first quarter. Royal Bank of Canada now owns 64,385 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 14,584 shares in the last quarter. Hedge funds and other institutional investors own 79.43% of the company’s stock.
Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) traded down 2.60% on Thursday, hitting $7.87. The company had a trading volume of 1,212,984 shares. The stock has a market cap of $1.08 billion, a PE ratio of 160.61 and a beta of 2.10. Achillion Pharmaceuticals Inc. has a 12 month low of $5.57 and a 12 month high of $10.95. The company has a 50-day moving average of $8.28 and a 200 day moving average of $8.46.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. During the same quarter last year, the business posted ($0.25) earnings per share. Analysts anticipate that Achillion Pharmaceuticals Inc. will post ($0.61) EPS for the current fiscal year.
A number of brokerages have weighed in on ACHN. Zacks Investment Research raised Achillion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $9.25 price objective on the stock in a report on Tuesday. Jefferies Group reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a report on Monday, September 26th. Chardan Capital lifted their price objective on Achillion Pharmaceuticals from $4.00 to $5.00 and gave the company a “sell” rating in a report on Friday, September 23rd. Wedbush began coverage on Achillion Pharmaceuticals in a report on Thursday, September 22nd. They issued an “outperform” rating and a $13.00 price objective on the stock. Finally, FBR & Co began coverage on Achillion Pharmaceuticals in a report on Thursday, September 15th. They issued an “outperform” rating and a $16.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $10.73.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.